Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

INTRODUCTION: For prophylaxis of hereditary angioedema (HAE) attacks, replacement therapy with human C1-inhibitor (C1-INH) treatment is approved and available as intravenous [C1-INH(IV)] (Cinryze(®)) and subcutaneous [C1-INH(SC)] HAEGARDA(®) preparations. In the absence of a head-to-head comparative...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Allergy Asthma Clin Immunol
Главные авторы: Bernstein, Jonathan A., Li, Huamin Henry, Craig, Timothy J., Manning, Michael E., Lawo, John-Philip, Machnig, Thomas, Krishnarajah, Girishanthy, Fridman, Moshe
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407188/
https://ncbi.nlm.nih.gov/pubmed/30899278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-019-0328-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы